Drugs / LY3493269
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05794243 | Mar → Jun 2023 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT04682106 | May → Nov 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04498390 | Sep → Dec 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04515576 | Aug 2020 → Mar 2021 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04178733 | Jan → May 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3493269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04515576 ↗ |
| Route | Subcutaneous | “Administered SC” NCT04178733 ↗ |